| Literature DB >> 17936161 |
Dean J Kereiakes1, Paul S Teirstein, Ian J Sarembock, David R Holmes, Mitchell W Krucoff, William W O'Neill, Ron Waksman, David O Williams, Jeffrey J Popma, Maurice Buchbinder, Roxana Mehran, Ian T Meredith, Jeffrey W Moses, Gregg W Stone.
Abstract
Percutaneous coronary intervention (PCI) has played an integral role in the therapeutic management strategies for patients who present with either acute coronary syndromes or stable angina pectoris. The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial enrolled patients with chronic stable angina and at least 1 significant (> or =70%) angiographic coronary stenosis who were randomly assigned to an initial treatment of either PCI in conjunction with optimal medical therapy or optimal medical therapy alone. Although the initial management strategy of PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events, improvement in angina-free status and a reduction in the requirement for subsequent revascularization was observed. An in-depth analysis of the COURAGE trial design and execution is provided.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17936161 DOI： 10.1016/j.jacc.2007.07.063
Source DB: PubMed Journal: J Am Coll Cardiol ISSN： 0735-1097 Impact factor: 24.094